What is the recommended treatment for acute gouty arthritis and long‑term urate‑lowering therapy?

Treatment of Gouty Arthritis

For acute gouty arthritis, treat immediately with colchicine, NSAIDs, or corticosteroids (choosing based on comorbidities), and when urate-lowering therapy (ULT) is indicated, start it during the acute flare with mandatory anti-inflammatory prophylaxis for 3-6 months. 1

Acute Gout Flare Management

First-Line Options for Acute Attacks

Choose one of three equally effective options based on patient-specific contraindications 1, 2:

• Colchicine: Effective for acute flares, particularly when started early 2, 3
• NSAIDs: Equally effective option for pain and inflammation control 2, 3, 4
• Corticosteroids (oral or intramuscular): Alternative when colchicine or NSAIDs are contraindicated 1, 2

Combination therapy with two agents can be used for severe flares 4, though the choice should account for comorbidities like chronic kidney disease, cardiovascular disease, and hypertension 3, 5.

Refractory Cases

• IL-1 inhibitors are now established as an option for flares refractory to standard therapies 2

Long-Term Urate-Lowering Therapy (ULT)

Indications for Starting ULT

Initiate ULT in patients with 3:

• Two or more flare-ups per year
• Chronic kidney disease
• Presence of tophi
• Urolithiasis
• Chronic gouty arthritis
• Joint damage

Timing of ULT Initiation

Start ULT during the acute flare rather than waiting for resolution 1. This conditional recommendation is based on time efficiency, patient motivation during symptomatic periods, and evidence showing no significant extension of flare duration or severity 1.

First-Line ULT Agents

• Allopurinol: Consensus first-line agent 3, 4

  • Start at low dose (particularly in CKD patients) and titrate upward 1
  • Patients with CKD may require doses above 300 mg/day to achieve target serum urate 1

• Febuxostat: Alternative xanthine oxidase inhibitor, but associated with increased all-cause and cardiovascular mortality, therefore not routinely recommended as first choice 3

Adjunctive Uricosuric Agents

• Probenecid: Start at low dose (500 mg once or twice daily) with gradual titration 1
• Other uricosuric agents (sulfinpyrazone, benzbromarone) can serve as adjuncts 2

Agents to Avoid as First-Line

Pegloticase is strongly recommended against as first-line therapy 1 due to cost, safety concerns, and favorable benefit-to-harm ratios of other options, despite moderate evidence supporting its efficacy.

Mandatory Anti-Inflammatory Prophylaxis During ULT Initiation

Strong Recommendation

Always initiate concomitant anti-inflammatory prophylaxis when starting ULT 1. This strong recommendation is based on 8 RCTs and 2 observational studies showing reduced flare rates 1.

Prophylaxis Options

Choose from 1:

• Colchicine
• NSAIDs
• Prednisone/prednisolone

Duration

Continue prophylaxis for 3-6 months minimum, not less than 3 months 1. Shorter durations are associated with flares upon cessation 1. After stopping, monitor for flare activity and continue prophylaxis as needed if flares persist 1.

Treat-to-Target Strategy

Use a treat-to-target management strategy with ULT dose titration guided by serial serum urate measurements rather than fixed-dose therapy 1. This approach is strongly recommended for all patients receiving ULT 1.

Critical Pitfalls to Avoid

• Do not withhold ULT initiation until after flare resolution—this delays definitive treatment and risks patient non-return 1
• Never start ULT without anti-inflammatory prophylaxis—this precipitates additional flares 1
• Do not stop prophylaxis before 3 months—premature cessation leads to breakthrough flares 1
• Avoid fixed-dose ULT without titration—many patients require dose escalation to achieve target serum urate 1
• Do not underdose allopurinol in CKD patients—they often need >300 mg/day despite renal impairment 1